Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism.
The nitroimidazole misonidazole (MISO) and related compounds have been shown to enhance the response of tumours to cytotoxic agents, and often to improve their therapeutic indices. Previous experiments suggested inhibition of cytotoxic drug metabolism as a mechanism. We have now investigated the effects of MISO and related compounds on drug metabolism in mice, and the results can be summarised as follows. (1) MISO and related compounds inhibit drug-metabolising enzymes, as measured by pentobarbitone sleep-time and zoxazolamine paralysis-time. (2) Enzyme inhibition is primarily dependent on lipophilicity, with maximum inhibition exhibited by the most active chemosensitizers. (3) MISO significantly slowed the clearance of pentobarbitone, aminopyrine and the cytotoxic agent chlorambucil, but had no effect on renal function or protein binding. These data support the view that inhibition of cytotoxic drug metabolism may be an important factor in chemosensitization.
D000632:Aminopyrine / Q000378:metabolism; D000818:Animals; D002699:Chlorambucil / Q000378:metabolism; D005260:Female; D007677:Kidney Function Tests; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009593:Nitroimidazoles / Q000494:pharmacology*; D010243:Paralysis / Q000139:chemically induced; D010424:Pentobarbital / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D015049:Zoxazolamine / Q000378:metabolism
D009593:Nitroimidazoles; D004364:Pharmaceutical Preparations; D000632:Aminopyrine; D002699:Chlorambucil; D015049:Zoxazolamine; D010424:Pentobarbital